Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Industry Faces Wave of Personal Injury Suits; Avandia To Test Honed Skills

Executive Summary

Some of the biggest names in product liability litigation will be flocking to a conference in Chicago July 13 to focus on one drug: Avandia. Mark Lanier, who won the largest jury verdict against Vioxx, is co-chairing the event. Other headliners include Christopher Seeger, a lead plaintiffs attorney in the federal Vioxx litigation, and Karen Barth Menzies, who has spearheaded dozens of cases against antidepressant products

You may also be interested in...



Charting The Course Of Product Liability: From Yasmin/Yaz To Actos

Bayer’s birth control pills Yasmin and Yaz face the most pharmaceutical product liability actions in federal court followed by Pfizer’s Prempro and GlaxoSmithKline’s Avandia. While GSK has settled the bulk of cases before a single trial, Merck and Novartis are winning Fosamax and Aredia jury verdicts.

GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting

The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company

GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting

The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel